IL6 and pancreatic neoplasm: Consistent with the repressed angiogenetic potency, FH535 also significantly decreased the levels of pancreatic cancer cell–secreted pro-angiogenic VEGF, interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-α (Figure 5I).